United States Biotechnology & Medical Research

Protalix Biotherapeutics Inc (PLX)

Track

Ticker: PLX Exchange: ASE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Protalix Biotherapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 19 Dec 2025
Value US$1,992,998.40 | Price 119.29 | Shares 56,389 (-12.7%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-23 2025-12-19 B Purchase
2.6
Bashan Dror

PRESIDENT AND CEO

Executive Director
56,389 -12.7%
119.29
US$1,992,998 		56,389 -12.7% 119.29 US$1,992,998
2025-11-19 2025-11-18 S Sale
1.3
Bar-Shalev Amos
Non-Executive Director
64,768 -7.5%
185.62
US$3,764,391 		64,768 -7.5% 185.62 US$3,764,391
2025-08-12 2025-06-10 B Purchase
3.7
Schwartz Aharon
Non-Executive Director
75,499 +12.4%
14.10
US$1,879,335 		75,499 +12.4% 14.10 US$1,879,335
2023-10-20 2023-10-19 B Purchase
2.6
Bashan Dror

PRESIDENT AND CEO

Executive Director
16,129 +13.9%
1.41
US$22,742 		16,129 +13.9% 1.41 US$22,742
2023-10-20 2023-10-19 B Purchase
2.6
Bashan Dror

PRESIDENT AND CEO

Executive Director
48,387 +71.2%
1.40
US$67,742 		48,387 +71.2% 1.40 US$67,742
2023-01-05 2023-01-03 B Purchase
3.7
Schwartz Aharon
Non-Executive Director
110,000 +171.9%
1.42
US$155,815 		110,000 +171.9% 1.42 US$155,815
2022-04-13 2022-04-11 B Purchase
2.6
Bashan Dror

President and CEO

Executive Director
68,000 +inf%
1.50
US$102,000 		68,000 +inf% 1.50 US$102,000
2021-06-03 2021-06-03 S Sale
4.0
Dexcel Pharma Technologies Ltd.
Large shareholder
857,506 -19.1%
2.25
US$1,932,304 		857,506 -19.1% 2.25 US$1,932,304
2021-06-03 2021-06-02 S Sale
4.0
Dexcel Pharma Technologies Ltd.
Large shareholder
61,211 -1.3%
2.56
US$156,553 		61,211 -1.3% 2.56 US$156,553
2020-04-13 2020-04-07 B Purchase
3.7
Schwartz Aharon
Non-Executive Director
64,000 +inf%
2.43
US$155,264 		64,000 +inf% 2.43 US$155,264
2017-05-16 2017-05-16 B Purchase Manor Moshe

President & CEO

Executive Director
50,000 +inf%
0.81
US$40,500 		50,000 +inf% 0.81 US$40,500
2016-12-06 2016-12-02 S Sale Camber Capital Management LLC Large shareholder
2,500,000 -18.8%
0.32
US$792,000 		2,500,000 -18.8% 0.32 US$792,000
2015-12-15 2015-12-14 B Purchase Maimon Yossi

Vice President & CFO

Officer
10,000 +inf%
0.78
US$7,800 		10,000 +inf% 0.78 US$7,800
2015-10-20 2015-10-19 B Purchase Camber Capital Management LLC Large shareholder
423 +0.0%
1.03
US$436 		423 +0.0% 1.03 US$436
2015-10-20 2015-10-19 B Purchase Camber Capital Management LLC Large shareholder
4,000,000 +43.1%
1.00
US$4,000,000 		4,000,000 +43.1% 1.00 US$4,000,000
2014-08-15 2014-08-13 S Sale Bio-Cell Ltd Large shareholder
4,400,000 -30.4%
2.47
US$10,868,000 		4,400,000 -30.4% 2.47 US$10,868,000
2014-08-15 2014-08-13 S Sale Bronfeld Zeev Non-Executive Director Large shareholder
4,400,000 -30.4%
2.47
US$10,868,000 		4,400,000 -30.4% 2.47 US$10,868,000
2013-08-16 2013-08-15 S Sale Akirov Alfred Non-Executive Director
2,330 -0.0%
5.07
US$11,813 		2,330 -0.0% 5.07 US$11,813
2013-08-16 2013-08-14 S Sale Akirov Alfred Non-Executive Director
5,000 -0.1%
5.08
US$25,400 		5,000 -0.1% 5.08 US$25,400
2013-08-16 2013-08-14 S Sale Akirov Alfred Non-Executive Director
5,000 -0.1%
5.07
US$25,350 		5,000 -0.1% 5.07 US$25,350
2013-08-16 2013-08-14 S Sale Akirov Alfred Non-Executive Director
100,000 -2.0%
5.05
US$505,000 		100,000 -2.0% 5.05 US$505,000
2013-03-14 2013-03-12 S Sale Akirov Alfred Non-Executive Director
10,000 -0.2%
5.70
US$57,000 		10,000 -0.2% 5.70 US$57,000
2013-03-12 2013-03-11 S Sale Akirov Alfred Non-Executive Director
5,000 -0.1%
5.71
US$28,550 		5,000 -0.1% 5.71 US$28,550
2013-03-12 2013-03-11 S Sale Akirov Alfred Non-Executive Director
10,000 -0.2%
5.72
US$57,200 		10,000 -0.2% 5.72 US$57,200
2013-03-12 2013-03-11 S Sale Akirov Alfred Non-Executive Director
3,000 -0.1%
5.75
US$17,250 		3,000 -0.1% 5.75 US$17,250
2013-03-12 2013-03-11 S Sale Akirov Alfred Non-Executive Director
300 -0.0%
5.79
US$1,737 		300 -0.0% 5.79 US$1,737
2013-03-12 2013-03-08 S Sale Akirov Alfred Non-Executive Director
1,898 -0.0%
5.95
US$11,293 		1,898 -0.0% 5.95 US$11,293
2013-03-12 2013-03-08 S Sale Akirov Alfred Non-Executive Director
2,500 -0.0%
5.92
US$14,800 		2,500 -0.0% 5.92 US$14,800
2013-03-12 2013-03-08 S Sale Akirov Alfred Non-Executive Director
2,500 -0.0%
5.91
US$14,775 		2,500 -0.0% 5.91 US$14,775
2013-03-12 2013-03-08 S Sale Akirov Alfred Non-Executive Director
10,000 -0.2%
5.82
US$58,200 		10,000 -0.2% 5.82 US$58,200
2013-03-08 2013-03-07 S Sale Akirov Alfred Non-Executive Director
3,435 -0.1%
5.73
US$19,683 		3,435 -0.1% 5.73 US$19,683
2013-03-08 2013-03-07 S Sale Akirov Alfred Non-Executive Director
5,000 -0.1%
5.71
US$28,550 		5,000 -0.1% 5.71 US$28,550
2013-03-08 2013-03-06 S Sale Akirov Alfred Non-Executive Director
700 -0.0%
5.71
US$3,997 		700 -0.0% 5.71 US$3,997
2013-03-08 2013-03-06 S Sale Akirov Alfred Non-Executive Director
2,000 -0.0%
5.69
US$11,380 		2,000 -0.0% 5.69 US$11,380
2013-03-08 2013-03-06 S Sale Akirov Alfred Non-Executive Director
2,000 -0.0%
5.68
US$11,360 		2,000 -0.0% 5.68 US$11,360
2012-05-04 2012-05-02 PlS Planned sale Almon Einat Brill

SVP, Product Development

Officer
166,848 -100.0%
7.13
US$1,189,626 		166,848 -100.0% 7.13 US$1,189,626
2012-05-04 2012-05-02 PlS Planned sale Aviezer David

President & CEO

Executive Director
450,000 -100.0%
7.13
US$3,208,500 		450,000 -100.0% 7.13 US$3,208,500
2012-05-04 2012-05-02 PlS Planned sale Maimon Yossi

VP, Chief Financial Officer

Officer
125,964 -100.0%
7.13
US$898,123 		125,964 -100.0% 7.13 US$898,123
2010-10-06 2010-10-06 PlS Planned sale Almon Einat Brill

VP, Product Development

Officer
15,000 -100.0%
9.29
US$139,350 		15,000 -100.0% 9.29 US$139,350
2010-10-06 2010-10-05 PlS Planned sale Almon Einat Brill

VP, Product Development

Officer
20,000 -100.0%
9.08
US$181,600 		20,000 -100.0% 9.08 US$181,600
2010-09-08 2010-09-07 PlS Planned sale Maimon Yossi

VP, Chief Financial Officer

Officer
31,500 -100.0%
8.16
US$257,040 		31,500 -100.0% 8.16 US$257,040
2010-09-08 2010-09-07 PlS Planned sale Almon Einat Brill

VP, Product Development

Officer
22,500 -100.0%
8.16
US$183,600 		22,500 -100.0% 8.16 US$183,600
2010-08-09 2010-08-06 PlS Planned sale Shaaltiel Yoseph

Executive VP, R&D

Executive Director
4,619 -0.6%
7.00
US$32,333 		4,619 -0.6% 7.00 US$32,333
2010-03-25 2010-03-25 PlS Planned sale Shaaltiel Yoseph

Executive VP, R&D

Executive Director
50,000 -5.4%
7.00
US$350,000 		50,000 -5.4% 7.00 US$350,000
2010-03-25 2010-03-24 PlS Planned sale Shaaltiel Yoseph

Executive VP, R&D

Executive Director
202,700 -17.8%
7.08
US$1,435,116 		202,700 -17.8% 7.08 US$1,435,116
2009-12-09 2009-12-02 B Purchase Bar-Shalev Amos Non-Executive Director
680 +68.0%
8.20
US$5,576 		680 +68.0% 8.20 US$5,576
2009-12-09 2009-12-02 B Purchase Bar-Shalev Amos Non-Executive Director
1,000 +inf%
8.68
US$8,680 		1,000 +inf% 8.68 US$8,680
2009-11-13 2009-11-12 S Sale Hurvitz Eli Non-Executive Director
250,000 -14.2%
10.76
US$2,690,000 		250,000 -14.2% 10.76 US$2,690,000
2009-11-13 2009-11-12 S Sale Hurvitz Eli Non-Executive Director
1,121,967 -38.9%
10.00
US$11,219,670 		1,121,967 -38.9% 10.00 US$11,219,670
2009-10-21 2009-10-21 PlS Planned sale Aviezer David

CEO and President

Executive Director
34,238 -100.0%
9.36
US$320,468 		34,238 -100.0% 9.36 US$320,468
2009-10-21 2009-10-20 PlS Planned sale Aviezer David

CEO and President

Executive Director
60,000 -100.0%
9.45
US$567,000 		60,000 -100.0% 9.45 US$567,000
2009-10-19 2009-10-19 PlS Planned sale Almon Einat Brill

VP, Product Development

Officer
38,320 -100.0%
9.43
US$361,358 		38,320 -100.0% 9.43 US$361,358
2009-10-19 2009-10-19 PlS Planned sale Shaaltiel Yoseph

Executive VP, R&D

Executive Director
43,120 -3.3%
9.43
US$406,622 		43,120 -3.3% 9.43 US$406,622
2009-10-19 2009-10-16 PlS Planned sale Almon Einat Brill

VP, Product Development

Officer
23,680 -100.0%
9.39
US$222,355 		23,680 -100.0% 9.39 US$222,355
2009-10-19 2009-10-16 PlS Planned sale Maimon Yossi

VP, Chief Financial Officer

Officer
40,300 -100.0%
9.35
US$376,805 		40,300 -100.0% 9.35 US$376,805
2009-10-19 2009-10-16 PlS Planned sale Shaaltiel Yoseph

Executive VP, R&D

Executive Director
25,680 -1.9%
9.39
US$241,135 		25,680 -1.9% 9.39 US$241,135
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
974 -0.0%
7.55
US$7,354 		974 -0.0% 7.55 US$7,354
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
2,300 -0.0%
7.54
US$17,342 		2,300 -0.0% 7.54 US$17,342
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
1,700 -0.0%
7.53
US$12,801 		1,700 -0.0% 7.53 US$12,801
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
1,100 -0.0%
7.52
US$8,272 		1,100 -0.0% 7.52 US$8,272
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
750 -0.0%
7.51
US$5,632 		750 -0.0% 7.51 US$5,632
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
12,300 -0.2%
7.50
US$92,250 		12,300 -0.2% 7.50 US$92,250
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
3,716 -0.0%
7.48
US$27,796 		3,716 -0.0% 7.48 US$27,796
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
3,200 -0.0%
7.47
US$23,904 		3,200 -0.0% 7.47 US$23,904
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
1,800 -0.0%
7.45
US$13,410 		1,800 -0.0% 7.45 US$13,410
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
50,900 -0.7%
7.44
US$378,696 		50,900 -0.7% 7.44 US$378,696
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
5,596 -0.1%
7.43
US$41,578 		5,596 -0.1% 7.43 US$41,578
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
1,400 -0.0%
7.42
US$10,388 		1,400 -0.0% 7.42 US$10,388
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
8,284 -0.1%
7.41
US$61,384 		8,284 -0.1% 7.41 US$61,384
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
13,200 -0.2%
7.40
US$97,680 		13,200 -0.2% 7.40 US$97,680
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
1,600 -0.0%
7.39
US$11,824 		1,600 -0.0% 7.39 US$11,824
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
9,254 -0.1%
7.38
US$68,295 		9,254 -0.1% 7.38 US$68,295
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
4,179 -0.1%
7.37
US$30,799 		4,179 -0.1% 7.37 US$30,799
2009-09-11 2009-09-10 S Sale FROST PHILLIP MD ET AL Large shareholder
5,821 -0.1%
7.35
US$42,784 		5,821 -0.1% 7.35 US$42,784
2009-09-11 2009-09-09 S Sale FROST PHILLIP MD ET AL Large shareholder
1,216 -0.0%
7.62
US$9,266 		1,216 -0.0% 7.62 US$9,266
Explore more

More insider trading research around Protalix Biotherapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America